Polynovo Limited
0.57
EUR
0.00
(0.00%)
ISIN
AU000000PNV0
Return %
Stock
S&P 500
1Y
-19.72
14.20
3Y
-16.18
81.12
5Y
-50.92
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Bruce Peatey
- Full Time Employees
- 301
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 320 Lorimer Street Port Melbourne VIC Australia 3207
- IPO Date
- Nov 26, 1998
- Website
- polynovo.com
- Similar Companies
- Business
- PolyNovo Limited is an Australian-based medical device company that designs, manufactures, and sells innovative biodegradable medical devices utilizing its patented NovoSorb bioabsorbable polymer technology. The company's core products include the NovoSorb Biodegradable Temporizing Matrix (BTM), a synthetic, biodegradable dermal scaffold that facilitates dermal regeneration following surgery, trauma, or burns. It also offers NovoSorb MTX, designed for single-stage grafting in burns, chronic, and surgical wounds, and is developing solutions for hernia repair, breast sling applications, and orthopedic devices. Additional pipeline products include the NovoSorb Dermal Beta Cell, an intracutaneous ectopic pancreas designed for type 1 diabetes treatment. PolyNovo operates primarily in Australia, New Zealand, the United States, the United Kingdom, Ireland, and emerging international markets. The company was incorporated in 1998 and is headquartered in Port Melbourne, Victoria, Australia. Recently, PolyNovo has focused on expanding its global operations and product offerings, including obtaining four new patents within the NovoSorb polymer family covering hernia and breast-related devices. The company anticipates a positive impact from proposed changes to U.S. Medicare reimbursement for outpatient wound care that align with its product portfolio, expected to enhance competitiveness through flat-rate reimbursement favoring clinically effective and cost-efficient options. PolyNovo continues to drive growth through commercial sales of NovoSorb BTM and MTX worldwide, expanding indications and markets to treat a wider range of patients with acute complex wounds. The company remains actively engaged in developing new medical technologies and strategic initiatives to augment its presence in chronic wound care and reconstructive surgery segments. PolyNovo Limited is listed on the Australian Securities Exchange under the ticker PNV.AX, employs over 300 staff, and sustained revenue growth in recent years driven by increasing global adoption of its products. The company is committed to advancing medical treatment through innovative biodegradable polymer solutions aimed at improving patient outcomes in complex wound and tissue regeneration care.
Company News
PolyNovo Limited (CALZF) Q4 2026 Earnings Call Transcript
PolyNovo Limited (CALZF) Q2 2026 Earnings Call Transcript